Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MiNK Therapeutics, Inc.INKT · Entity 52 | Director | September 01, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MiNK Therapeutics, Inc.
Report date September 01, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,691 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 1,233 · Balance 4,691 F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 2, 2026 14:21 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,233 | $10.95 | $13,501.35 |
DisclosureSEC source: 0001193125-26-379524 · ownership.xml · nonDerivative · entry 1 Holcomb John Bradley · CIK 0002092279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,691 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| June 01, 2026 Filed Jun 2, 2026 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,091 | $12.38 | $13,506.58 |
DisclosureSEC source: 0001193125-26-253474 · ownership.xml · nonDerivative · entry 2 Holcomb John Bradley · CIK 0002092279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,458 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| March 02, 2026 Filed Jun 2, 2026 20:05 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,239 | $10.90 | $13,505.10 |
DisclosureSEC source: 0001193125-26-253474 · ownership.xml · nonDerivative · entry 1 Holcomb John Bradley · CIK 0002092279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,367 F2 · price: Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:10 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantCommon Stock | 1,128 | $11.09 | $12,509.52 |
DisclosureSEC source: 0001193125-25-306679 · ownership.xml · nonDerivative · entry 1 Holcomb John Bradley · CIK 0002092279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,128 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date. Read SEC document |
| September 23, 2025 Filed Apr 30, 2026 20:30 UTC | MiNK Therapeutics, Inc. INKT · Entity 52 | GrantStock Option (Right to Buy) · Derivative | 4,174 | $0.00 Strike: $14.92 | $0.00 |
DisclosureSEC source: 0001193125-26-197482 · ownership.xml · derivative · entry 1 Holcomb John Bradley · CIK 0002092279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,174 Underlying: Common Stock · 4,174 shares Expires 2035-09-23 F1 · derivative.exercise_date: The Stock Options were awarded in accordance with the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan on September 23, 2025 and will vest in three equal annual installments on each of September 23, 2026, 2027 and 2028 (provided Dr. Holcomb maintains a service relationship with the company through each such vesting date). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.